Description
Verify COA Lab Results:
https://portal.ils-lab.com/verify/ehqVmiiNmKWk55Iv
Product Overview: Tirzepatide
Tirzepatide is a novel, synthetic 39-amino acid linear peptide engineered as a dual agonist for both the Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) receptors. Formulated with a C20 fatty diacid diacid moiety attached via a linker to allow high-affinity albumin binding, Tirzepatide exhibits an extended plasma half-life of approximately 5 days. By dual-activating GIP and GLP-1 receptors in the pancreas, brain, and adipose tissue, Tirzepatide serves as a primary research compound for evaluating glucose homeostasis, delayed gastric motility, central appetite regulation, and profound adiposity loss.
Primary Research Applications & Reasons for Study
- Dual GIP/GLP-1 Receptor Co-Agonism: Evaluating the synergistic metabolic advantages of activating both incretin pathways simultaneously over mono-selective GLP-1 receptor agonists.
- Glucose-Dependent Insulin & Glucagon Dynamics: Upregulating glucose-stimulated insulin secretion (GSIS) from pancreatic beta cells while suppressing inappropriate postprandial glucagon release from alpha cells.
- Central Satiety & Gastric Motility Regulation: Studying brainstem/hypothalamic anorectic signaling shifts and delayed gastric emptying kinetics in obesity models.
- Adipose Tissue Energy Expenditure: Investigating GIP-mediated increases in white adipose tissue (WAT) lipid buffering capacity, insulin sensitivity, and fat oxidation rates.
Expected Research Results & Timeline Metrics
- Phase 1 / Hours 1–24
Acute Glycemic Suppression & Delayed Gastric Emptying: Immediate, statistically significant drops in postprandial blood glucose spikes and rapid initiation of central satiety signaling. - Phase 2 / Weeks 1–4
Pancreatic Beta-Cell Sensitization & Weight Reduction: Marked improvements in HOMA-IR insulin resistance metrics, reduced daily feed intake, and initial total adipose mass reduction. - Phase 3 / Weeks 8–24+
Profound Adiposity Loss & Hepatic Clearance: Up to ~15–22%+ reduction in total body weight in diet-induced obesity models, accompanied by significant clearance of intrahepatic lipid accumulation (steatosis).
Key Research Benefits
- Superior Dual-Incretin Efficacy: Outperforms selective GLP-1 mono-agonists (such as Semaglutide) in glucose control and body weight reduction parameters.
- Extended Half-Life & Albumin Binding: C20 fatty acid modification enables high-affinity reversible binding to plasma albumin, facilitating sustained, multi-day experimental protocols.
- Cardiometabolic Optimization: Demonstrates broad improvements across systemic lipid profiles, blood pressure markers, and systemic inflammatory parameters in metabolic disease models.
- Next-Generation Metabolic Standard: Premier benchmark compound for studying type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), and obesity pathophysiology.
THIS PRODUCT IS INTENDED SOLELY FOR IN VITRO LABORATORY RESEARCH AND EXPERIMENTAL PURPOSES. It is strictly prohibited for human consumption, clinical trials, therapeutic administration, cosmetic use, or veterinary application. This product is not an FDA-approved drug, medical food, or dietary supplement. It is not intended to diagnose, treat, cure, or prevent any disease, illness, or medical condition. Any handling, reconstitution, or experimentation involving this chemical compound must be conducted strictly by qualified, trained laboratory professionals utilizing appropriate containment and personal protective equipment in accordance with scientific biosafety standards. Buyers and users assume full liability for compliance with local, state, and federal laws regarding the handling and possession of research compounds.